Jon Wigginton, MD currently serves as Chief Medical Officer and Senior Vice President of Clinical Development at MacroGenics, Inc., a Maryland biotechnology company focused on immunotherapeutic approaches for cancer and autoimmune disease. Dr. Wigginton previously served as Therapeutic Area Head of Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb (BMS), where he led the early clinical development of the BMS Immuno-Oncology portfolio including anti-PD-1, anti-PD-L1 and various immunotherapy combinations including anti-CTLA-4/anti-PD-1 among others. He also served in a governance leadership role for discovery efforts in immuno-oncology at BMS. Prior to joining BMS, Dr. Wigginton served as Director of Clinical Oncology at Merck Research Laboratories, where he led early- and late-stage clinical development teams for small molecules and biologics. During his academic career, Dr. Wigginton held several positions at the National Cancer Institute, Center for Cancer Research (NCI-CCR), including Head of Investigational Biologics Section, Pediatric Oncology Branch, where he led an integrated basic science and early clinical research effort focused on combination immunotherapy. Dr. Wigginton also served previously as President of the International Society for the Biological Therapy of Cancer (now the Society for Immunotherapy of Cancer). He received his B.S. in Biology and his M.D. from the University of Michigan.